Skip to main content
. Author manuscript; available in PMC: 2009 Dec 3.
Published in final edited form as: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):459–466. doi: 10.1097/QAI.0b013e31815bace2

TABLE 2.

Step 1 Median (Range) Fasting Lipid Values (mg/dL)

Screening* Week 8 Absolute Change P Percent Change P
Fish oil (n = 47)
 TG 665 (402 to 2980) 362 (133 to 1278) −283 (−2019 to 682) <0.001 −46% (−87 to 114) <0.001
 LDL-C 86 (31 to 152) 108 (60 to 227) 30 (−48 to 120) <0.001 37% (−44 to 348) <0.001
 HDL-C 31 (21 to 43) 32 (22 to 51) 1 (−9 to 18) 0.198 4% (−24 to 55) 0.074
 TC 246 (147 to 457) 236 (128 to 450) −15 (−204 to 105) 0.028 −7% (−45 to 42) 0.043
 Non-HDL-C 210 (125 to 436) 204 (100 to 414) −13 (−207 to 87) 0.018 −7% (−47 to 40) 0.026
Fenofibrate (n = 48)
 Serum TG 694.5 (401 to 1922) 338.5 (103 to 1476) −367 (−1466 to 319) <0.001 −58% (−90 to 67) <0.001
 LDL-C 73 (30 to 160) 110.5 (63 to 191) 31.5 (−45 to 101) <0.001 46% (−33 to 233) <0.001
 HDL-C 30 (21 to 42) 33.5 (7 to 53) 4 (−17 to 24) <0.001 13% (−71 to 110) <0.001
 TC 243 (158 to 447) 211.5 (140 to 321) −21.5 (−289 to 60) <0.001 −10% (−65 to 28) <0.001
 Non-HDL-C 210.5 (132 to 421) 178.5 (112 to 314) −27 (−300 to 57) <0.001 −13% (−71 to 31) <0.001
*

Note that screening values differ from Table 1 because not all subjects had week 8 evaluations and the numbers of subjects differ from the baseline assessment.

Signed rank test.

TC indicates total cholesterol.